Stocktoria
LENSAR, Inc. LNSR
LENSAR, Inc. (LNSR) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $58.4M at a -58.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.02 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.087 |
| Retained earnings / assets | -2.486 |
| EBIT / assets | -0.344 |
| Equity / liabilities | -0.311 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LNSR | LENSAR, Inc. | 2/9 | -10.17 | — | +9.2% |
| CVRX | CVRx, Inc. | 3/9 | -15.5 | — | +10.4% |
| APYX | Apyx Medical Corp | 5/9 | -0.11 | — | +9.9% |
| CARL | CARLSMED, INC. | 5/9 | 4.88 | — | +85.9% |
| PDEX | PRO DEX INC | 6/9 | 8.16 | 21.9 | +23.7% |
| SI | SHOULDER INNOVATIONS, INC. | 4/9 | 7.68 | — | +49.6% |
| RCEL | AVITA Medical, Inc. | 3/9 | — | — | +11.5% |
About LENSAR, Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
FAQ
Is LNSR financially healthy?
LENSAR, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LNSR pay a dividend?
No, LENSAR, Inc. does not currently pay a dividend.
How profitable is LNSR?
In FY2025, LENSAR, Inc. had a net margin of -58.7%.
What is the analyst price target for LNSR?
The average Wall-Street price target for LENSAR, Inc. is $8.50, about 35.1% above the recent price, from 2 analysts.
Is LNSR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LENSAR, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.